Background
Individual patient data meta-analysis by the Early Breast Cancer Trialists' Collaborative Group (EBCTCG). 10,801 women from 17 randomized trials comparing radiotherapy after BCS vs BCS alone. Included patients with pN0, pN+, and unknown nodal status; all had technically adequate surgery. This landmark meta-analysis quantified the long-term OS benefit of RT after BCS.
Interventions and follow up
Arm A: BCS + whole breast RT
Arm B: BCS alone (no RT)
Primary endpoint: 10-year recurrence and 15-year breast cancer death
mFollow up: Up to 15 year
Arm B: BCS alone (no RT)
Primary endpoint: 10-year recurrence and 15-year breast cancer death
mFollow up: Up to 15 year
Results
10-year any recurrence: 19.3% (RT) vs 35.0% (no RT), absolute reduction 15.7%
10-year first recurrence (locoregional): 7.8% vs 26.0%, absolute reduction 18.2%
15-year breast cancer mortality: 21.4% (RT) vs 25.2% (no RT), absolute reduction 3.8% (P=.00005)
15-year overall mortality: 25.2% vs 28.5%, absolute reduction 3.3% (P=.005)
Ratio: For every 4 local recurrences prevented, approximately 1 breast cancer death prevented (4:1 ratio)
10-year first recurrence (locoregional): 7.8% vs 26.0%, absolute reduction 18.2%
15-year breast cancer mortality: 21.4% (RT) vs 25.2% (no RT), absolute reduction 3.8% (P=.00005)
15-year overall mortality: 25.2% vs 28.5%, absolute reduction 3.3% (P=.005)
Ratio: For every 4 local recurrences prevented, approximately 1 breast cancer death prevented (4:1 ratio)
Adverse events
Main adverse events: RT-related cardiac death (0.4% at 15 years) and non-breast cancer death offset some benefit in certain subgroups, but net absolute breast cancer mortality benefit remained 3.8% overall.
Conclusions
Radiotherapy after BCS reduces 10-year any recurrence by ~16% and 15-year breast cancer mortality by ~4% in absolute terms. The 4:1 ratio (4 recurrences prevented per 1 death prevented) provides a robust framework: patients at very low absolute risk of local recurrence gain minimal mortality benefit from RT, while those at higher risk benefit proportionally more.
Key Limitations
Key Limitations: Older trials included; systemic treatment landscape has changed substantially (modern chemotherapy, HER2-targeted therapy, aromatase inhibitors all reduce local recurrence, potentially reducing the absolute benefit of RT). Heterogeneous patient populations across 17 trials. The 4:1 ratio is an average across populations — individual risk-stratified estimates would refine RT benefit predictions. RT techniques included cobalt and older linear accelerators; modern RT has lower late toxicities.
Clinical Context
The EBCTCG 2011 meta-analysis is the foundational document supporting RT after BCS for all stages. The 4:1 ratio is widely cited in patient counseling and guideline development. It forms the basis for omission discussions in low-risk populations (elderly, T1, ER+, N0) where LR risk is sufficiently low that the absolute mortality benefit from RT approaches zero.
References